Results 131 to 140 of about 535,272 (262)

Amplification of Endoplasmic Reticulum Stress via Inhibiting Lipid Droplet Formation to Enhance Chemodynamic Immunotherapy

Advanced Science, EarlyView.
An endoplasmic reticulum (ER)‐targeted chemodynamic nanoagent (TCBQ/iLD‐ER NPs) comprising •OH‐generating tetrachloro‐1,4‐benzoquinone (TCBQ) and lipid droplets (LDs) formation inhibitor (iLD) is developed for chemodynamic immunotherapy of tumors. After ingestion by cancer cells, TCBQ/iLD‐ER NPs preferentially accumulate in the ER and react with ER ...
Huilan Cai, Shaoru Zhuang, Yang Zhu, Rujiang Ao, Meili Yu, Tingting Cui, Jun Wang, Xuegang Niu, Hongwei Huang, Shanshan Peng, Yu He, Lisen Lin, Huanghao Yang   +12 more
wiley   +1 more source

Editorial: Role of the IL-23/IL-17 Pathway in Chronic Immune-Mediated Inflammatory Diseases: Mechanisms and Targeted Therapies

Frontiers in Immunology, 2021
Elisabetta Bianchi, Elisabetta Bianchi, Matteo Vecellio, Matteo Vecellio, Lars Rogge, Lars Rogge   +5 more
doaj   +1 more source

Interleukin-23 in lung and airway diseases: from pathogenesis to precision-guided therapeutic targeting. [PDF]

Front Pharmacol
Nayak BB, Rajesh R, Teppan J, Gogg T, Böhm E.   +4 more
europepmc   +1 more source

Distinct roles for interleukin-23 receptor signaling in regulatory T cells in sporadic and inflammation-associated carcinogenesis. [PDF]

Front Oncol, 2023
Jacobse J, Pilat JM, Li J, Brown RE, Kwag A, Buendia MA, Choksi YA, Washington MK, Williams CS, Markham NO, Short SP, Goettel JA.   +11 more
europepmc   +1 more source

Triple‐Negative Breast Cancer Cells Utilize IL8 and CXCL1 to Suppress NK Cells’ Function and Facilitate Cancer Metastasis

Advanced Science, EarlyView.
Triple‐negative breast cancer (TNBC) cells evade natural killer (NK) cell immunity by secreting IL8 and CXCL1. These chemokines suppress NK cells’ function via CXCR1/2 and enhance cancer cells’ survival through PD‐L1 upregulation and BCL‐2 anti‐apoptotic signaling.
Mingheng Yuan, Hongmei Yang, Renfei Wu, Meng Hao, Xiangpeng Chu, Chuxia Deng, Kathy Qian Luo   +6 more
wiley   +1 more source

Psychiatric safety of bimekizumab versus interleukin-23 inhibitors in psoriasis: A real-world TriNetX cohort study. [PDF]

JAAD Int
Tolete C, Friedman A, Calderon J, Tjahjono L.   +3 more
europepmc   +1 more source

Orchestrated Engineered Polyphenol‐Peptide Condensates Coupled With β‐GP Reverses Diabetic Osteoporosis by Remodeling Mitophagy

Advanced Science, EarlyView.
A multifunctional β‐GP@EGCG‐E7 nanoplatform is engineered by polyphenol–peptide condensation and phosphate loading. Bone‐targeted delivery, antioxidant and anti‐inflammatory activity, and mitophagy restoration are integrated in one system, enabling protection of osteoblasts and endothelial cells and promoting bone regeneration under diabetic ...
Xiuyun Xu, Meiqin Zhang, Ting Wu, Erfan Wei, Andrei Y. Hancharou, Zeying Wang, Zijuan Wang, Letian Lv, Likun Wu, Xingtong Pan, Qiyue Zhu, Xinyi Dong, Hao Liu, Yongsheng Zhou   +13 more
wiley   +1 more source

Interleukin-23 receptor signaling impairs the stability and function of colonic regulatory T cells. [PDF]

Cell Rep, 2023
Jacobse J, Brown RE, Li J, Pilat JM, Pham L, Short SP, Peek CT, Rolong A, Washington MK, Martinez-Barricarte R, Byndloss MX, Shelton C, Markle JG, Latour YL, Allaman MM, Cassat JE, Wilson KT, Choksi YA, Williams CS, Lau KS, Flynn CR, Casanova JL, Rings EHHM, Samsom JN, Goettel JA.   +24 more
europepmc   +1 more source

BCMA‐Engineered Dendritic Cell‐Derived Exosomes as Bi‐Functional Therapeutics Orchestrating Cytokine Sequestration and Immune Activation for Multiple Myeloma

Advanced Science, EarlyView.
A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng, Chao He, Zhibin He, Hongbo Chen, Fang Cheng, Yongjiang Zheng   +5 more
wiley   +1 more source

New Interleukin-23 Antagonists' Use in Crohn's Disease. [PDF]

Pharmaceuticals (Basel)
Biskup L, Semeradt J, Rogowska J, Chort W, Durko Ł, Małecka-Wojciesko E.   +5 more
europepmc   +1 more source